

17 February 2022

ASX Code: MXC

LSE Code: MXC

Results of General Meeting

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the results from the Company's General Meeting held on Wednesday, 16 February 2022, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all resolutions put to the meeting were voted by poll, with all resolutions carried by a clear majority.

Details of the proxy voting and voting outcomes for all resolutions put to the meeting are set out in the attached report.

--Ends--

Authorised for release by the Chairman, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
 CEO & Managing Director
 +61 8 6382 3390
info@mgcpharma.com.au

UK Broker – Turner Pope

Andy Thacker
 +44 203 657 0050
info@turnerpope.com

MGC Pharmaceuticals Ltd

David Lim
 Company Secretary
 +61 8 6382 3390
info@mgcpharma.com.au

UK PR Advisors – Tavistock

Tim Pearson
 +44 207 920 3150
mgcpharma@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels



A
S
X

R
E
L
E
A
S
E

**MGC PHARMACEUTICALS LTD
GENERAL MEETING
Wednesday, 16 February 2022
Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 - Ratification of prior issue of Placement Shares	Ordinary	496,783,096 89.40%	55,267,583 9.94%	3,705,099 0.66%	724,764	500,495,355 90.06%	55,267,583 9.94%	724,764	Carried
2 - Ratification of prior issue of Broker Options	Ordinary	561,447,507 89.11%	64,941,972 10.31%	3,705,099 0.58%	985,964	565,159,766 89.69%	64,941,972 10.31%	985,964	Carried
3 - Ratification of prior issue of Mercer Shares	Ordinary	487,636,265 89.21%	55,276,528 10.11%	3,715,524 0.68%	9,852,225	491,358,949 89.89%	55,276,528 10.11%	9,852,225	Carried
4 - Approval to issue Consideration Shares	Ordinary	612,805,788 97.26%	13,632,948 2.16%	3,705,099 0.58%	936,807	616,518,047 97.84%	13,632,948 2.16%	936,807	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.